/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

S

Saengsuree Jootar

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

124

Papers

2.2K

Citations

24

h-index

47

i10-index

Saengsuree Jootar is an academic researcher. The author has contributed to research in topics: Chronic Myeloid Leukemia Treatments & Chronic Lymphocytic Leukemia Research & Hematopoietic Stem Cell Transplantation. The author has an h-index of 24, co-authored 106 publications.

Research Topics

Chronic Myeloid Leukemia Treatments Chronic Lymphocytic Leukemia Research Hematopoietic Stem Cell Transplantation Eosinophilic Disorders and Syndromes Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers by this author

works

ENESTnd Update: Nilotinib (NIL) Vs Imatinib (IM) In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) and The Impact Of Early Molecular Response (EMR) and Sokal Risk At Diagnosis On Long-Term Outcomes

2013 · Blood · 47 citations

https://doi.org/10.1182/blood.v122.21.92.92

Giuseppe Saglio Andreas Hochhaus Timothy P. Hughes Richard E. Clark

Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand

2010 · Journal of Hematology & Oncology · 42 citations

https://doi.org/10.1186/1756-8722-3-1

Pimjai Niparuck Ladda Sorakhunpipitkul Vichai Atichartakarn Suporn Chuncharunee

Efficacy of Nilotinib Versus High-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses to Standard-Dose Imatinib (RE-NICE Multicenter Study)

2011 · Blood · 16 citations

https://doi.org/10.1182/blood.v118.21.2765.2765

Hyun‐Gyung Goh Saengsuree Jootar Hyeoung‐Joon Kim Hyeoung‐Joon Kim

Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients: 12 Months Result of Phase 3 Clinical Trial

2015 · Blood · 12 citations

https://doi.org/10.1182/blood.v126.23.476.476

Jae‐Yong Kwak Hawk Kim Jeong‐Ah Kim Young Rok

Efficacy and Safety of Radotinib in Chronic Phase Chronic Myeloid Leukemia Patients with Resistance or Intolerance to BCR-ABL Tyrosine Kinase Inhibitors: Radotinib Phase 2 Clinical Trial

2012 · Blood · 8 citations

https://doi.org/10.1182/blood.v120.21.695.695

Sung‐Hyun Kim Hari Menon Saengsuree Jootar Tapan Saikia

Nilotinib Or High-Dose Imatinib Compared With Standard-Dose Imatinib In Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses To Standard-Dose Imatinib: Including Updated Data From RE-Nice Study

2013 · Blood · 4 citations

https://doi.org/10.1182/blood.v122.21.1499.1499

Soo-Young Choi Sung‐Eun Lee Yun Jeong Oh Soo-Hyun Kim

Research topics

topics

Chronic Myeloid Leukemia Treatments

Chronic Lymphocytic Leukemia Research

Hematopoietic Stem Cell Transplantation

Eosinophilic Disorders and Syndromes

Myeloproliferative Neoplasms: Diagnosis and Treatment

Chat about Author

Papers

Chat

Click to start Chat